STAT+: Pharmalittle: Biogen Alzheimer’s drug slowed cognitive decline in a trial; European pharma warns energy costs may halt some generic production
Good morning, everyone, and how are you today? We are doing just fine, thank you, after a brief respite to observe ancient rituals. Now, though, we have returned to the usual routine of online meetings, calls, and deadlines. Some things are predictable, yes? So to cope, we are enjoying a cup of stimulation — chocolate raspberry is our flavor du jour — and we invite you to join us. Meanwhile, we have gathered a few items of interest to help you get moving on your own journey today, which we hope will be productive and meaningful. And of course, we encourage you to keep in touch. We are always on the prowl for new pen pals. …
An investigational Alzheimer’s disease treatment from Biogen and Eisai slowed the rate of cognitive decline by 27% in a clinical trial, meeting the goals of a closely tracked study and strengthening the case for regulatory approval as early as January, STAT reports. The positive result is welcome news for the millions of people living with Alzheimer’s and a big win for Eisai and Biogen, giving the companies a potential blockbuster product in the intravenous medicine, called lecanemab. For Biogen, which presided over the disastrous rollout of the Aduhelm treatment of Alzheimer’s, the potential approval of lecanemab presents a rare second chance at a multibillion-dollar market.
Continue to STAT+ to read the full story…
